CARsgen Therapeutics - The Bradford Era

Breaking News, Business, Local News

LECOM to acquire BRMC campus, skilled nursing facility

Inpatient, ER will close; outpatient services to continue

Sara Furlong

February 26, 2026

Lake Erie College of Osteopathic Medicine (LECOM) is in discussions with Kaleida Health to acquire the Bradford Regional Medical Center (BRMC) campus,...

Press Releases

CARsgen Announced 2024 Annual Results

CARsgen Therapeutics

March 19, 2025

SHANGHAI , March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR ...

Press Releases

CARsgen’s Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA

CARsgen Therapeutics

March 3, 2025

SHANGHAI , March 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell thera...

Press Releases

CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease

CARsgen Therapeutics

February 28, 2025

SHANGHAI , Feb. 27, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell thera...

Press Releases

CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

CARsgen Therapeutics

February 26, 2025

SHANGHAI , Feb. 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, " CARsgen Therapeutics "), a company focused on i...

Press Releases

CARsgen’s First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4

CARsgen Therapeutics

February 10, 2025

SHANGHAI , Feb. 9, 2025 /PRNewswire/ -- CAR sgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell thera...

Press Releases

CARsgen’s Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

CARsgen Therapeutics

January 20, 2025

SHANGHAI , Jan. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell thera...

Press Releases

CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

CARsgen Therapeutics

January 13, 2025

SHANGHAI , Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell thera...

Press Releases

CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy

CARsgen Therapeutics

December 31, 2024

SHANGHAI , Dec. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell thera...

Press Releases

CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)

CARsgen Therapeutics

December 30, 2024

SHANGHAI , Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell thera...